TY - CHAP
T1 - A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride
AU - Li, Sijing
AU - Motiño, Omar
AU - Lambertucci, Flavia
AU - Chen, Hui
AU - Anagnostopoulos, Gerasimos
AU - Montégut, Léa
AU - Nogueira-Recalde, Uxía
AU - Maiuri, Maria Chiara
AU - Kroemer, Guido
AU - Martins, Isabelle
N1 - Publisher Copyright:
© The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 2024.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD). Obesity is a known risk factor of NASH, which, in turn, increases the risk of developing cirrhosis (liver scarring) and hepatocellular carcinoma (HCC). In addition to being a potentially life-threatening condition, public health concerns surrounding NASH are amplified by the lack of FDA-approved treatments. Although various preclinical models reflecting both the histopathology and the pathophysiological progression of human NASH exist, most of these models are diet-based and require 6–13 months for NASH symptom manifestation. Here, we describe a simple and rapid-progression model of NASH and NASH-driven HCC in mice. Mice received a western diet equivalent (WD; i.e., a high-fat, high-fructose, and high-cholesterol diet), high-sugar water (23.1 g/L fructose and 18.9 g/L glucose), and weekly intraperitoneal injections of carbon tetrachloride (CCl4) at a dose of 0.2 μL/g of body weight. The resulting phenotype, consisting in liver fibrosis and HCC, appeared within 24 weeks of diet/treatment initiation and presented similar histological and transcriptomic features as human NASH and NASH-driven HCC, thereby supporting the adequacy of this preclinical model for the development and evaluation of drugs that can prevent or reverse these diseases.
AB - Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD). Obesity is a known risk factor of NASH, which, in turn, increases the risk of developing cirrhosis (liver scarring) and hepatocellular carcinoma (HCC). In addition to being a potentially life-threatening condition, public health concerns surrounding NASH are amplified by the lack of FDA-approved treatments. Although various preclinical models reflecting both the histopathology and the pathophysiological progression of human NASH exist, most of these models are diet-based and require 6–13 months for NASH symptom manifestation. Here, we describe a simple and rapid-progression model of NASH and NASH-driven HCC in mice. Mice received a western diet equivalent (WD; i.e., a high-fat, high-fructose, and high-cholesterol diet), high-sugar water (23.1 g/L fructose and 18.9 g/L glucose), and weekly intraperitoneal injections of carbon tetrachloride (CCl4) at a dose of 0.2 μL/g of body weight. The resulting phenotype, consisting in liver fibrosis and HCC, appeared within 24 weeks of diet/treatment initiation and presented similar histological and transcriptomic features as human NASH and NASH-driven HCC, thereby supporting the adequacy of this preclinical model for the development and evaluation of drugs that can prevent or reverse these diseases.
KW - Carbon tetrachloride (CCl4)
KW - Hepatocellular carcinoma (HCC)
KW - NASH-driven HCC
KW - Non-alcoholic fatty liver disease (NAFLD)
KW - Non-alcoholic steatohepatitis (NASH)
KW - Western diet
UR - http://www.scopus.com/inward/record.url?scp=85184458889&partnerID=8YFLogxK
U2 - 10.1007/978-1-0716-3694-7_4
DO - 10.1007/978-1-0716-3694-7_4
M3 - Chapter
C2 - 38315388
AN - SCOPUS:85184458889
T3 - Methods in Molecular Biology
SP - 57
EP - 65
BT - Methods in Molecular Biology
PB - Humana Press Inc.
ER -